Developing novel medicines for central nervous system diseases.
Autifony Therapeutics is an independent UK-based biotechnology company formed in 2011 as a spinout from GSK, which retains equity in the company.
The company is focused on the development of high-value, novel medicines to treat serious diseases of the central nervous system. It is funded by SV Life Sciences, Touchstone Innovations plc, Pfizer Venture Investments, International Biotechnology Trust plc, and UCL Ventures.
The lead clinical programmes build on the novel Kv3 family of potassium channels: AUT00206 is a very promising clinical-stage Kv3 modulator for the treatment of Fragile X syndrome, with FDA Orphan Drug Designation. AUT00201 is a potent, clinical-stage Kv3 modulator for the treatment of rare epilepsy syndromes.
Autifony’s preclinical-stage assets targeting Kv3 channels show huge potential to treat a broader range of CNS indications such as schizophrenia and age-related hearing loss.
